Jay Birnbaum

Dr. Jay Birnbaum, a Co-Founder and Board Member, is the inventor of the first method patent that laid the foundation the company’s subungual approach.

Dr. Birnbaum has more than 30 years of industry experience in discovery research, formulations, clinical R&D, regulatory, and marketing. He has been involved in the development and commercialization of numerous drugs, devices, and consumer products brands.

Prior to starting his own pharmaceutical consulting company in 1999, Dr. Birnbaum was Vice President, Global Project Management at Novartis/Sandoz, where he also had direct responsibility for the clinical development and commercialization of Lamisil®. He previously held various management positions at the Medical and Consumer Products Divisions of American Cyanamid Corporation (Wyeth).

Dr. Bimbaum has been published extensively for his work in drug development and is widely recognized as an expert in the field of onychomycosis. He is a Co-founder and former Chief Medical Officer of Kythera Biopharmaceuticals and has served as a member of Boards of Directors of Oculus Innovative Sciences, Excaliard Pharmaceuticals (acquired by Pfizer in 2011), and the Scientific Advisory Boards of many companies.